Caspian Oliai, MD
UCLA / Jonsson Comprehensive Cancer Center
Built from public records under this name as ClinicalTrials.gov spells it. A name can belong to more than one person, so each section says how its rows were tied to this name. No contact details are shown.
Trials
Studies that name Caspian Oliai, MD as principal investigator, study chair or study director, newest first. Live from ClinicalTrials.gov, fetched 2026-11-12 10:14 UTC. Open this list on ClinicalTrials.gov
- Ph1NCT05720988 · Tagraxofusp to Eradicate Measurable Residual Disease in Patients With Acute Myeloid LeukemiaJonsson Comprehensive Cancer Center · withdrawn · Acute Myeloid Leukemia · principal investigator
- Ph1/Ph2NCT05256641 · Acalabrutinib Maintenance for the Treatment of Patients With Large B-cell LymphomaJonsson Comprehensive Cancer Center · recruiting · Diffuse Large B-Cell Lymphoma, High-grade B-cell Lymphoma, Transformed Lymphoma · principal investigator
- Ph1NCT03904251 · CPX-351 and Gemtuzumab Ozogamicin in Treating Patients With Relapsed Acute Myeloid LeukemiaJonsson Comprehensive Cancer Center · terminated · Acute Myelogenous Leukemia · principal investigator
- Ph2NCT03825796 · CPX-351 Plus Enasidenib for Relapsed AMLJonsson Comprehensive Cancer Center · active not recruiting · Recurrent Acute Myeloid Leukemia · principal investigator
Grants
NIH projects from RePORTER, fetched 2026-11-12 10:14 UTC. A project is listed only when its grant number is on one of the trials above, or when the awardee institution matches an affiliation the registry gives for this name. Coverage is US federal funding only; UK and EU funders are not searched yet.
No NIH project could be tied to this name by a shared trial or a matching institution.
Most cited trial papers
PubMed returned no clinical-trial papers for this author name.